340B – A Critical Program for Community Health Centers

The 340B Drug Pricing Program is an essential source of support for Community Health Centers (CHCs), allowing them to stretch increasingly scarce federal resources and reinvest in patient care. The program allows CHCs to purchase outpatient drugs at significantly reduced costs. CHCs pass the savings on to their patients through reduced drug prices and invest additional savings to expand access and improve health outcomes.

CHC patients include people with low incomes, seniors, veterans, parents, and people with disabilities. Without the 340B program, these Americans would not have access to low-cost medications and essential health services. The cost of medicines can easily push them into poverty, disease, or even death.

Current Threats to the 340B Program

NACHC is concerned about ongoing actions by drug companies that threaten patient access to critical medicines and essential health services supported by the 340B Program. These attacks have diverted savings away from patient care and toward middlemen and corporate profits, ultimately tying the hands of health center doctors and other care providers and making America sicker, not healthier.

Latest from NACHC about 340B

NACHC Letter to HRSA on Manufacturers’ Unlawful 340B Policy (April 2026): View letter

NACHC Template Response to 340B Rebate RFI (April 2026)

340B Rebate Model Pilot Program (December 10, 2025): Check out NACHC’s resources, template letters, and webinars to prepare for a potential rebate model in the future.

NACHC Letter to Senate HELP Committee Regarding 340B (October 24, 2025): View letter

NACHC Resources Related to the New Terms and Conditions for the 330 Grant in 340B (July 31, 2025):

NACHC Letter to CMS and HRSA Regarding 340B and Rebate proposals (June 17, 2025): View letter

NACHC Statement (April 16, 2025): Response to Trump Administration Executive Order, “Lowering Drug Prices by Once Again Putting Americans First”

NACHC Urges Pharmaceutical Manufacturers to Reverse Harmful Restrictions (June 28, 2024): NACHC sent letters to Alkermes, Bausch+Lomb, Eli Lilly, and Sobi.

NACHC Partnership with ASAP340B

NACHC, alongside PhRMA, formed the Alliance to Save America’s 340B Program (ASAP 340B) to work toward a Congressional solution to improve the 340B program, preserving access to low-cost medication and essential services through CHCs while enhancing transparency and accountability. This partnership, which also includes patient, provider, and consumer advocates, aims to ensure the 340B program supports true safety-net providers and the communities they serve. NACHC is open to working collaboratively with all stakeholders in the 340B program.

Learn more about ASAP 340B and the group’s policy principles.